Background: There are no proven or approved second-line treatment options for patients
with advanced HCC. Based on promising activity in a second-line phase 2 study (Bruix, Eur
J Cancer 2013), we evaluated regorafenib, an oral multikinase inhibitor, in patients with
intermediate or advanced HCC who had disease progression on sorafenib. Methods: In this
double-blind, placebo-controlled trial, adults with HCC Barcelona Clinic Liver Cancer
(BCLC) stage B or C who received sorafenib for≥ 20 days at≥ 400 mg/day and had …

LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular
carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase
3 RESORCE trial | CiNii Research … LBA-03 Efficacy and safety of regorafenib versus
placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results
of the international, randomized phase 3 RESORCE trial …